Developer docs
API playgroundTry for free, no card

Search company profiles

Vantive

Full company profile

uuid02m97th

Namestring
Vantive
Legal namestring
Vantive Health LLC
Websiteurl
vantive.com
Company typeenum
Public
Founded yearint
2025
Descriptiontext

Vantive Health LLC is an independent, publicly traded healthcare company headquartered in Deerfield, Illinois, that was spun off from Baxter International Inc. in February 2025 and carries forward a 70-year legacy in kidney care and vital organ support therapies. The company designs, manufactures, and distributes medical devices for renal replacement therapy (HomeChoice peritoneal dialysis cycler, PrisMax, Prismaflex, Phoenix, PrismaLung+) and advanced dialyzers (Theranova with proprietary MCO membrane technology for HDx therapy), alongside peritoneal dialysis solutions and related pharmaceuticals. Its core platform architecture combines therapy hardware with the Sharesource Connectivity Platform — a two-way remote patient management system that has supported over 100 million home dialysis treatments across 10+ years — and the broader Vantive CONNECT digital suite, which includes the MyPD patient app, PD Telecare proactive monitoring, EMR integration, Home Navigators support, and Vantive Pinpoint Delivery tracking.

Vantive generates revenue through multiple streams: hardware and consumable sales to healthcare providers and dialysis centers (dialyzers, PD solutions, cyclers, acute therapy machines), recurring revenue from digital and remote patient management platforms, professional services and training (including VR-based clinician education), and licensing/distribution arrangements such as the exclusive U.S./Canada distribution of Spectral Medical's PMX hemoadsorption therapy. Its go-to-market combines direct enterprise sales, regional commercial websites across North America, EMEA, Asia Pacific and Latin America, channel partnerships with major U.S. dialysis providers (U.S. Renal Care, Innovative Renal Care), and event-driven engagement at major nephrology and critical care congresses. Vantive serves two principal customer segments: patients with chronic kidney disease and end-stage renal disease (alongside their clinicians) and ICU/critical care settings requiring continuous renal replacement therapy and multi-organ support, with a stated mission to expand home dialysis penetration from the current ~11% global rate among dialysis patients.

Short descriptiontext

Vantive is an independent vital organ therapy company spun off from Baxter in 2025 that develops dialysis devices, CRRT systems, the Sharesource remote patient management platform, and advanced services to serve kidney disease patients, dialysis providers, and ICU clinicians across 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersDeerfield, United States
HQ citystring
Deerfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney dialysis products, renal care therapies, continuous renal replacement therapy, home peritoneal dialysis, remote patient monitoring
Industry4 codes
PRIMARYHLAHAKAG
Home Dialysis Equipment & Remote Monitoring
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLAFAEAG
Home Dialysis Support & Training Providers
NAICS code2 codes
  • Ambulatory Health Care Services621
  • Home Health Care Services621610
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Home Health Care Services8082
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Renal Care & Vital Organ Therapy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medical Devices and Dialysis Equipment
TypeHardware Sales
Description

Vantive designs, manufactures, and distributes medical devices including dialysis machines, dialyzers (Theranova), peritoneal dialysis cyclers, and acute care therapy systems (PrisMax, Prismaflex). Products are sold to healthcare providers, dialysis centers, and directly to patients for home use.

vantive.com
2Pharmaceuticals and Dialysis Solutions
TypeHardware Sales
Description

Vantive manufactures and distributes pharmaceutical products and dialysis solutions essential for renal care including peritoneal dialysis solutions and related consumables.

vantive.com
3Digital Solutions and Remote Patient Management
TypeSubscription Recurring
Description

Vantive provides digital health platforms (Sharesource, Vantive CONNECT) that enable remote patient monitoring and management, supporting healthcare providers with data-driven insights and proactive care coordination.

vantive.com
4Advanced Services and Education
TypeProfessional Services
Description

Vantive offers advanced services including training programs, technical support, patient support services (PD Telecare), and educational resources for clinicians and patients.

vantive.com
5PMX Hemoadsorption Distribution (Spectral Medical)
TypeLicensing Royalties
Description

Vantive is the exclusive distributor of PMX (Polymyxin B Hemoadsorption) in the U.S. and Canada and has non-exclusive rights to distribute Endotoxin Activity Assay (EAA) globally. PMX is a therapeutic device for treating endotoxic septic shock.

vantive.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vantive develops, manufactures, and distributes medical devices, pharmaceuticals, and digital health platforms used in kidney care and vital organ support. Its portfolio includes dialysis machines, dialyzers, peritoneal dialysis cyclers, CRRT systems, dialysis solutions, and the Sharesource/Vantive CONNECT remote patient management ecosystem. The company sells these therapies, digital solutions, and advanced services to healthcare providers, dialysis centers, hospitals, and ICU departments globally, and operates a fully-integrated home dialysis ecosystem (HomeAdvantage) for patients with chronic kidney disease and end-stage renal disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Sharesource use associated with 45% lower all-cause mortality and 69% lower hospitalization rates for home PD patients
+5 more records
Product overview1 text field

Vantive is a vital organ therapy company offering an integrated portfolio of therapies, digital solutions, and advanced services for kidney care and organ support. The core therapy offerings include peritoneal dialysis (PD) systems (HomeChoice), continuous renal replacement therapy devices (PrisMax, Prismaflex, Phoenix), and advanced dialysis technologies (Theranova dialyzer enabling HDx therapy). The digital ecosystem is anchored by the Sharesource Connectivity Platform for remote patient management, powered by Vantive CONNECT suite, which integrates with EMR systems and includes patient-facing tools (MyPD app) and clinical support (PD Telecare Program). The company also offers patient resources including PD Empowers and Global Travel Club. HomeAdvantage represents the fully-integrated home therapy ecosystem combining these products and services.

Product and service16 records
1Sharesource Connectivity Platform
CategoryDigital health platform
2PrisMax System
CategoryTherapy device (CRRT)
3Prismaflex System
CategoryTherapy device (CRRT)
4Phoenix Dialysis System
CategoryTherapy device (dialysis)
5HomeChoice
CategoryTherapy device (home peritoneal dialysis)
6Theranova Dialyzer
CategoryTherapy device (dialyzer)
7PrismaLung+
CategoryTherapy device (ECCO₂R)
8Vantive CONNECT
CategoryDigital platform suite
9HomeAdvantage
CategoryIntegrated home therapy ecosystem
10MyPD
CategoryPatient mobile application
11PD Telecare Program
CategoryRemote patient support service
12Vantive Learning Services
CategoryClinician training service
13Vantive Pinpoint Delivery
CategorySupply chain / logistics service
14Home Navigators
CategoryPatient support service
15PMX Hemoadsorption
CategoryTherapy device (distributed)
16Vantive CONNECT Success Model
CategoryDigital services framework
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-31
Description

Multi-year strategic agreement to expand access to home dialysis, enhance patient experience, and strengthen support for care teams. U.S. Renal Care partners with nephrologists across 32 states caring for 37,000+ kidney disease patients. Partnership includes Sharesource platform, EMR integration, and PD Telecare services.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-16
Description

Multi-year strategic agreement focused on expanding access to home dialysis, enhancing the therapy experience, and empowering patients and care teams through home dialysis care. IRC operates 230+ dialysis programs across 28 U.S. states serving ~16,000 patients. Partnership includes Sharesource Connectivity Platform, EMR integration, and PD Telecare Program.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-07-01
Description

Vantive is Spectral's exclusive distributor of PMX (Polymyxin B Hemoadsorption) in the U.S. and Canada and has non-exclusive rights to distribute EAA (Endotoxin Activity Assay) globally. PMX is a therapeutic device for treating endotoxic septic shock. Vantive supports Spectral's clinical trials including the Tigris trial and plans to commercialize both EAA and PMX upon FDA approval.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

bioMérieux is developing the CCL14 biomarker for use in assessing risk of patients with moderate or severe AKI developing persistent severe AKI. Vantive is committed to advancing research and delivering solutions for personalized AKI management in collaboration with bioMérieux.

Strategic tierMinorTypeOthers
Description

Vantive endorses and strongly supports GS1 standards for healthcare to improve patient safety and drive increased efficiency and integrity in the supply chain. Industry-wide adoption of these standards is encouraged.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fresenius Medical Care is the world's largest provider of dialysis products and services, manufacturing hemodialysis machines, dialyzers, and PD systems, and operating thousands of dialysis clinics. It directly competes with Vantive across dialysis equipment, supplies, and consumables.

TypeDirect peer
Description

Outset Medical designs the Tablo Hemodialysis System, an enterprise-grade dialysis console for use in hospitals, clinics, and homes. It is a direct competitor in the home dialysis segment where Vantive's HomeAdvantage and Sharesource also compete.

TypeDirect peer
Description

B. Braun's Avitum division manufactures dialysis machines, dialyzers, and CRRT systems, and operates dialysis centers globally. It is a direct competitor in renal care equipment and supplies, overlapping with Vantive's PrisMax, Theranova, and PD portfolios.

TypeDirect peer
Description

Quanta develops the SC+ portable hemodialysis system designed for flexible use across in-center, home, and acute settings. It is a direct competitor targeting the same home dialysis opportunity as Vantive's HomeAdvantage ecosystem.

5Nipro Corporation
TypeDirect peer
Description

Nipro manufactures dialysis equipment, dialyzers, and related consumables under its Renal Care business. It competes directly with Vantive in dialyzers and PD products globally.

6Asahi Kasei Medical
TypeDirect peer
Description

Asahi Kasei Medical is a leading manufacturer of dialysis membranes (e.g., Vitabran, Vitapheal) and therapeutic apheresis products. It is a direct competitor to Vantive in dialyzer technology and blood purification.

TypeDirect peer
Description

Nikkiso's Medical division produces dialysis machines, CRRT systems, and blood purification devices. Its product overlap with Vantive's PrisMax/Prismaflex acute therapies makes it a direct competitor in renal care equipment.

TypeBroad incumbent
Description

DaVita is one of the largest U.S. dialysis service providers, operating thousands of clinics and treating hundreds of thousands of patients. As a major purchaser of Vantive's equipment and supplies, it is an important channel partner and competitor influence in shaping dialysis standards.

TypeBroad incumbent
Description

Baxter was Vantive's parent company until the February 2025 spinoff and continues to operate in adjacent hospital products, IV solutions, and Pumps. While no longer a direct renal care competitor, Baxter retains related portfolios and shared IP exposure.

TypeEmerging player
Description

Spectral Medical is the developer of PMX (Polymyxin B Hemoadsorption) and the EAA biomarker, with Vantive as exclusive U.S./Canada distributor. Although primarily a partner, Spectral overlaps with Vantive in the endotoxic septic shock and blood purification space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vantive

Renal Care & Vital Organ Therapyvantive.com

Vantive is an independent vital organ therapy company spun off from Baxter in 2025 that develops dialysis devices, CRRT systems, the Sharesource remote patient management platform, and advanced services to serve kidney disease patients, dialysis providers, and ICU clinicians across 100+ countries.

What Vantive does

Vantive Health LLC is an independent, publicly traded healthcare company headquartered in Deerfield, Illinois, that was spun off from Baxter International Inc. in February 2025 and carries forward a 70-year legacy in kidney care and vital organ support therapies. The company designs, manufactures, and distributes medical devices for renal replacement therapy (HomeChoice peritoneal dialysis cycler, PrisMax, Prismaflex, Phoenix, PrismaLung+) and advanced dialyzers (Theranova with proprietary MCO membrane technology for HDx therapy), alongside peritoneal dialysis solutions and related pharmaceuticals. Its core platform architecture combines therapy hardware with the Sharesource Connectivity Platform — a two-way remote patient management system that has supported over 100 million home dialysis treatments across 10+ years — and the broader Vantive CONNECT digital suite, which includes the MyPD patient app, PD Telecare proactive monitoring, EMR integration, Home Navigators support, and Vantive Pinpoint Delivery tracking.

Vantive generates revenue through multiple streams: hardware and consumable sales to healthcare providers and dialysis centers (dialyzers, PD solutions, cyclers, acute therapy machines), recurring revenue from digital and remote patient management platforms, professional services and training (including VR-based clinician education), and licensing/distribution arrangements such as the exclusive U.S./Canada distribution of Spectral Medical's PMX hemoadsorption therapy. Its go-to-market combines direct enterprise sales, regional commercial websites across North America, EMEA, Asia Pacific and Latin America, channel partnerships with major U.S. dialysis providers (U.S. Renal Care, Innovative Renal Care), and event-driven engagement at major nephrology and critical care congresses. Vantive serves two principal customer segments: patients with chronic kidney disease and end-stage renal disease (alongside their clinicians) and ICU/critical care settings requiring continuous renal replacement therapy and multi-organ support, with a stated mission to expand home dialysis penetration from the current ~11% global rate among dialysis patients.

Vantive firmographics

Firmographics
Name
Vantive
Legal name
Vantive Health LLC
Website
https://vantive.com
Company type
Public
Founded year
2025
Operating status
Operating
Short description
Vantive is an independent vital organ therapy company spun off from Baxter in 2025 that develops dialysis devices, CRRT systems, the Sharesource remote patient management platform, and advanced services to serve kidney disease patients, dialysis providers, and ICU clinicians across 100+ countries.
Ownership category
akta.pro rank

Vantive industry classification

Industry
Product category
Renal Care & Vital Organ Therapy
NAICS
Ambulatory Health Care Services (621), Home Health Care Services (621610)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Home Health Care Services (8082), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAHAKAG
Home Dialysis Equipment & Remote Monitoring
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLAFAEAG
Home Dialysis Support & Training Providers

Keywords

  • Kidney dialysis products
  • Renal care therapies
  • Continuous renal replacement therapy
  • Home peritoneal dialysis
  • Remote patient monitoring

Where Vantive is headquartered

Location

Headquarters

HQ city
Deerfield
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Vantive business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Devices and Dialysis Equipment: Vantive designs, manufactures, and distributes medical devices including dialysis machines, dialyzers (Theranova), peritoneal dialysis cyclers, and acute care therapy systems (PrisMax, Prismaflex). Products are sold to healthcare providers, dialysis centers, and directly to patients for home use.
  2. Pharmaceuticals and Dialysis Solutions: Vantive manufactures and distributes pharmaceutical products and dialysis solutions essential for renal care including peritoneal dialysis solutions and related consumables.
  3. Digital Solutions and Remote Patient Management: Vantive provides digital health platforms (Sharesource, Vantive CONNECT) that enable remote patient monitoring and management, supporting healthcare providers with data-driven insights and proactive care coordination.
  4. Advanced Services and Education: Vantive offers advanced services including training programs, technical support, patient support services (PD Telecare), and educational resources for clinicians and patients.
  5. PMX Hemoadsorption Distribution (Spectral Medical): Vantive is the exclusive distributor of PMX (Polymyxin B Hemoadsorption) in the U.S. and Canada and has non-exclusive rights to distribute Endotoxin Activity Assay (EAA) globally. PMX is a therapeutic device for treating endotoxic septic shock.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Vantive product offering

Product offering

Core offering

Vantive develops, manufactures, and distributes medical devices, pharmaceuticals, and digital health platforms used in kidney care and vital organ support. Its portfolio includes dialysis machines, dialyzers, peritoneal dialysis cyclers, CRRT systems, dialysis solutions, and the Sharesource/Vantive CONNECT remote patient management ecosystem. The company sells these therapies, digital solutions, and advanced services to healthcare providers, dialysis centers, hospitals, and ICU departments globally, and operates a fully-integrated home dialysis ecosystem (HomeAdvantage) for patients with chronic kidney disease and end-stage renal disease.

Product overview

Vantive is a vital organ therapy company offering an integrated portfolio of therapies, digital solutions, and advanced services for kidney care and organ support. The core therapy offerings include peritoneal dialysis (PD) systems (HomeChoice), continuous renal replacement therapy devices (PrisMax, Prismaflex, Phoenix), and advanced dialysis technologies (Theranova dialyzer enabling HDx therapy). The digital ecosystem is anchored by the Sharesource Connectivity Platform for remote patient management, powered by Vantive CONNECT suite, which integrates with EMR systems and includes patient-facing tools (MyPD app) and clinical support (PD Telecare Program). The company also offers patient resources including PD Empowers and Global Travel Club. HomeAdvantage represents the fully-integrated home therapy ecosystem combining these products and services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sharesource Connectivity Platform
  • PrisMax System
  • Prismaflex System
  • Phoenix Dialysis System
  • HomeChoice
  • Theranova Dialyzer
  • PrismaLung+
  • Vantive CONNECT
  • HomeAdvantage
  • MyPD
  • PD Telecare Program
  • Vantive Learning Services
  • Vantive Pinpoint Delivery
  • Home Navigators
  • PMX Hemoadsorption
  • Vantive CONNECT Success Model

Quantifiable outcome

  • Sharesource use associated with 45% lower all-cause mortality and 69% lower hospitalization rates for home PD patients
  • +5 more outcomes

Companies that use Vantive

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Vantive technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature8 records

Vantive partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • U.S. Renal CareflagshipStrategic or Co-development Partner · 31 October 2025Multi-year strategic agreement to expand access to home dialysis, enhance patient experience, and strengthen support for care teams. U.S. Renal Care partners with nephrologists across 32 states caring for 37,000+ kidney disease patients. Partnership includes Sharesource platform, EMR integration, and PD Telecare services.
  • Innovative Renal CareflagshipStrategic or Co-development Partner · 16 July 2025Multi-year strategic agreement focused on expanding access to home dialysis, enhancing the therapy experience, and empowering patients and care teams through home dialysis care. IRC operates 230+ dialysis programs across 28 U.S. states serving ~16,000 patients. Partnership includes Sharesource Connectivity Platform, EMR integration, and PD Telecare Program.
  • Spectral MedicalcoreTechnology or Integration · 1 July 2022Vantive is Spectral's exclusive distributor of PMX (Polymyxin B Hemoadsorption) in the U.S. and Canada and has non-exclusive rights to distribute EAA (Endotoxin Activity Assay) globally. PMX is a therapeutic device for treating endotoxic septic shock. Vantive supports Spectral's clinical trials including the Tigris trial and plans to commercialize both EAA and PMX upon FDA approval.
  • bioMérieuxminorStrategic or Co-development PartnerbioMérieux is developing the CCL14 biomarker for use in assessing risk of patients with moderate or severe AKI developing persistent severe AKI. Vantive is committed to advancing research and delivering solutions for personalized AKI management in collaboration with bioMérieux.
  • GS1minorOthersVantive endorses and strongly supports GS1 standards for healthcare to improve patient safety and drive increased efficiency and integrity in the supply chain. Industry-wide adoption of these standards is encouraged.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Vantive competitors and assessment

Company assessment

Direct peers

  • Fresenius Medical Care: Fresenius Medical Care is the world's largest provider of dialysis products and services, manufacturing hemodialysis machines, dialyzers, and PD systems, and operating thousands of dialysis clinics. It directly competes with Vantive across dialysis equipment, supplies, and consumables.
  • Outset Medical: Outset Medical designs the Tablo Hemodialysis System, an enterprise-grade dialysis console for use in hospitals, clinics, and homes. It is a direct competitor in the home dialysis segment where Vantive's HomeAdvantage and Sharesource also compete.
  • B. Braun: B. Braun's Avitum division manufactures dialysis machines, dialyzers, and CRRT systems, and operates dialysis centers globally. It is a direct competitor in renal care equipment and supplies, overlapping with Vantive's PrisMax, Theranova, and PD portfolios.
  • Quanta Dialysis Technologies: Quanta develops the SC+ portable hemodialysis system designed for flexible use across in-center, home, and acute settings. It is a direct competitor targeting the same home dialysis opportunity as Vantive's HomeAdvantage ecosystem.
  • Nipro Corporation: Nipro manufactures dialysis equipment, dialyzers, and related consumables under its Renal Care business. It competes directly with Vantive in dialyzers and PD products globally.
  • Asahi Kasei Medical: Asahi Kasei Medical is a leading manufacturer of dialysis membranes (e.g., Vitabran, Vitapheal) and therapeutic apheresis products. It is a direct competitor to Vantive in dialyzer technology and blood purification.
  • Nikkiso: Nikkiso's Medical division produces dialysis machines, CRRT systems, and blood purification devices. Its product overlap with Vantive's PrisMax/Prismaflex acute therapies makes it a direct competitor in renal care equipment.

Broad incumbents

  • DaVita: DaVita is one of the largest U.S. dialysis service providers, operating thousands of clinics and treating hundreds of thousands of patients. As a major purchaser of Vantive's equipment and supplies, it is an important channel partner and competitor influence in shaping dialysis standards.
  • Baxter International: Baxter was Vantive's parent company until the February 2025 spinoff and continues to operate in adjacent hospital products, IV solutions, and Pumps. While no longer a direct renal care competitor, Baxter retains related portfolios and shared IP exposure.

Emerging players

  • Spectral Medical: Spectral Medical is the developer of PMX (Polymyxin B Hemoadsorption) and the EAA biomarker, with Vantive as exclusive U.S./Canada distributor. Although primarily a partner, Spectral overlaps with Vantive in the endotoxic septic shock and blood purification space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Vantive social profiles

Digital presence

Vantive compliance and trust

Trust signal

Compliance1 record

Vantive financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vantive leadership team

Management profile

Number of profiles

Profiles6 records

Vantive funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vantive M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vantive

What does Vantive do?

Vantive develops, manufactures, and distributes medical devices, pharmaceuticals, and digital health platforms used in kidney care and vital organ support. Its portfolio includes dialysis machines, dialyzers, peritoneal dialysis cyclers, CRRT systems, dialysis solutions, and the Sharesource/Vantive CONNECT remote patient management ecosystem. The company sells these therapies, digital solutions, and advanced services to healthcare providers, dialysis centers, hospitals, and ICU departments globally, and operates a fully-integrated home dialysis ecosystem (HomeAdvantage) for patients with chronic kidney disease and end-stage renal disease.

Is Vantive a public or private company?

Vantive is a public company. It is classified as public and is currently operating.

When was Vantive founded?

Vantive was founded in 2025.

Where is Vantive based?

Vantive is headquartered in Deerfield, United States, in the North America region.

How does Vantive make money?

Five revenue lines are on record. Medical Devices and Dialysis Equipment is the primary driver. The others are pharmaceuticals and Dialysis Solutions, digital Solutions and Remote Patient Management, advanced Services and Education and PMX Hemoadsorption Distribution (Spectral Medical).

Who are Vantive's main competitors?

Direct peers on record are Fresenius Medical Care, Outset Medical, B. Braun, Quanta Dialysis Technologies, Nipro Corporation, Asahi Kasei Medical and Nikkiso. Broad incumbents are DaVita and Baxter International. Spectral Medical is listed as an emerging player.

Does Vantive have an API?

No public API is recorded for Vantive.

What industry is Vantive in?

Vantive's product category is Renal Care & Vital Organ Therapy. Its primary akta.pro industry code is HLAHAKAG, Home Dialysis Equipment & Remote Monitoring, with a secondary code of HLALAFAC, Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support). Its NAICS code is 621 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Rockwell Medical: Vantive Hemodialysis Business Acquisition For Up To $170 Million Targets $450 Million In Annual RevenueRockwell Medical agreed to acquire Vantive's hemodialysis concentrates, equipment, water treatment, and services for up to $170 million, with an initial price of $125 million. The deal targets $400–450 million in annual revenue and includes Vantive's Italian manufacturing campus. Rockwell expects to close in mid-2027.GlobeNewswireSpectral Medical Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateSpectral Medical reported Q3 2026 revenue of $275,000, down 59% year-over-year, and a net income of $5.1 million. The company received $1.0 million from Vantive and closed a C$14 million convertible note offering, expecting to fund operations through the FDA PMA decision. A corporate update call is scheduled for December 10, 2026.LelezardVantive annonce la conclusion d'un accord portant sur la cession de la majorité de ses actifs dans le domaine de l'hémodialyse et des activités associées à Rockwell MedicalVantive announced a definitive agreement to sell the majority of its hemodialysis-related assets and activities to Rockwell Medical. The deal, expected to close in mid-2027, includes Vantive's hemodialysis concentrates, monitors, and water treatment systems, with the Medolla, Italy manufacturing plant transferring to Rockwell. The Vantive dialysis machine line is excluded.TradingViewRMTI: Vantive deal adds global dialysis reach; combined revenue projected at $400 million to $450 millionRockwell Medical acquired Vantive's dialysis machines, water systems, concentrates, services, and a large Italian manufacturing campus, extending global reach. Combined annual revenue is projected at $400 million to $450 million, with closing expected mid-2027 subject to approvals.NewswireVantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell MedicalVantive agreed to divest the majority of its hemodialysis assets and operations to Rockwell Medical. The deal includes concentrates, monitors, and water systems, excluding the dialyzer portfolio, and is expected to close in mid-2027. Ownership of Vantive's Italian manufacturing facility will transfer to Rockwell.Stock TitanRockwell Medical to buy most of Vantive's dialysis assetsVantive agreed to sell most of its hemodialysis assets and operations to Rockwell Medical, including concentrates, monitors, and water systems. The deal excludes Vantive's dialyzer portfolio and is expected to close in mid-2027. The transaction aims to sharpen Vantive's focus on home dialysis and critical care.PR NewswireVantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell MedicalVantive agreed to sell its hemodialysis assets and operations to Rockwell Medical, including concentrates, monitors, and water systems. The deal excludes Vantive's dialyzer portfolio and is expected to close in mid-2027. Ownership of Vantive's Italian manufacturing facility will transfer to Rockwell.Stock TitanRockwell Medical to Buy Vantive Assets: $125M Base PriceRockwell Medical agreed to acquire Vantive's hemodialysis concentrates, machines, water treatment systems, and related services for a $125 million base price, financed by term loans and a convertible note. The combined business is projected to generate $400–450 million in annual revenue, with closing expected mid-2027.ArkansasbusinessOrgan Therapy Firm Vantive Plans $100M Expansion of Mountain Home SiteVantive announced a $100 million expansion of its Mountain Home facility, expected to create 175 jobs over four years. The project adds a tubing line, sterilizers, compressors, and a chemistry lab. The site, opened by Baxter 60 years ago, currently employs about 800 people.Talk Business & PoliticsVantive announces $100 million investment in Mountain Home facility - Talk Business & PoliticsVantive announced a $100 million investment to expand its Mountain Home facility, creating up to 175 new jobs over four years, with 75 hired in the first year. The company will use the funds for new equipment and expansion projects, building on its 60-year history in the site.